



Figure S1: Flowchart of patients OpACIN-neo study. Number of patients included for mass spectrometry. For every patient, two plasma samples were analyzed: one baseline samples (pre-treatment) sample and one post-treatment (after neoadjuvant ICB therapy) sample at week 6. Mass spectrometry data was available for 83 patients that had measurements for both pre-treatment and post-treatment samples. Patients with no measurement for certain proteins (e.g. LRG1 and C7) were excluded from the corresponding analysis. NR; non-responding patients